Literature DB >> 12102748

Adoptive transfer of T-cell immunity.

Helmut W H G Kessels1, Monika C Wolkers, Ton N M Schumacher.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12102748     DOI： 10.1016/s1471-4906(02)02219-6

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


× No keyword cloud information.
  6 in total

1.  CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.

Authors:  Hui Zhao; Xueyan Xi; Lianxian Cui; Wei He
Journal:  Cell Mol Immunol       Date:  2011-09-12       Impact factor: 11.530

Review 2.  T-cell-mediated autoimmunity: novel techniques to characterize autoreactive T-cell receptors.

Authors:  Klaus Dornmair; Norbert Goebels; Hans-Ulrich Weltzien; Hartmut Wekerle; Reinhard Hohlfeld
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

Review 3.  Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Tuna Mutis
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

4.  Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.

Authors:  Tonia Mazzarella; Valeria Cambiaghi; Nathalie Rizzo; Lorenzo Pilla; Danilo Parolini; Elena Orsenigo; Annalisa Colucci; Giulio Modorati; Claudio Doglioni; Giorgio Parmiani; Cristina Maccalli
Journal:  Cancer Immunol Immunother       Date:  2011-12-30       Impact factor: 6.968

5.  Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray.

Authors:  Daniel S Chen; Yoav Soen; Tor B Stuge; Peter P Lee; Jeffrey S Weber; Patrick O Brown; Mark M Davis
Journal:  PLoS Med       Date:  2005-09-20       Impact factor: 11.069

6.  A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2012-08-03       Impact factor: 5.531
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.